Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
How do you use P1NP in your clinical practice to guide management of osteoporosis?
Related Questions
How frequently do you monitor for hypocalcemia in patients on romosozumab?
How do you approach management of osteoporosis in patients post lung transplant?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
